Sigrid Therapeutics reports positive results from consumer testing of SiPore®, a product intended for prediabetics, type 2 diabetics and obese people to control blood sugar levels

Stockholm, March 8, 2023. Sigrid Therapeutics, an innovative, consumer-focused health company, today presented the results of a consumer trial ahead of the launch of their clinically proven SiPore® technology for blood sugar control in prediabetics and type 2 diabetics. Two hundred and nine volunteers participated in the six-week program, with the majority of reviews being overwhelmingly positive after taking the SiPore® product.

During the program, the subjects consumed the product twice daily with their two main meals. The subjects' experiences and opinions were collected in a questionnaire before and after the program. No less than 94% of the users felt confident using SiPore®, 84% were satisfied with SiPore® and 84% would recommend SiPore® to a friend. The following statements resonated strongly with the participants: The substance is a natural mineral, it is clinically tested and is a Swedish product. See link to white paper below for individual views with regard to experiences regarding e.g. blood sugar control, weight loss and daily energy levels.

"While we have noted clinically significant effects of SiPore® technology in previous clinical trials including a 40% more pronounced HbA1c reduction compared to Metformin in prediabetics ^* , the overwhelmingly positive, subjective user reviews exceeded our expectations," said Sigrid Therapeutics Co-Founder and CEO, Sana Alajmovic.

“With even more inspiration to move forward in our development, we are now preparing to launch SiPore® 1) as a dietary supplement for the US market, 2) for the veterinary market, primarily for cats, and 3) in oral health. In parallel, we are developing the SiPore® technology as a medical device in the EU and will start a large clinical study in 287 patients who are either moderately or severely overweight and also have prediabetes or type 2 diabetes.”